Pontifax Management 4 G.P. (2015) Ltd.

CIK: 0001726334

Transaction Breakdown

Open Market Buys (P)1 (16.7%)

High conviction signal

Open Market Sales (S)4 (66.7%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)0 (0.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (16.7%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

KROS

Keros Therapeutics, Inc.

10% Owner

LBRX

LB PHARMACEUTICALS INC

10% Owner

Discretionary Trading P&L

Holdings

Transaction History (6 total)

KROS
Keros Therapeutics, Inc.
Oct 15, 2025
Sale(S)
Indirect
2.3M shares at avg. $17.75$40.6M
KROS
Keros Therapeutics, Inc.
Oct 15, 2025
Sale(S)
Indirect
1.1M shares at avg. $17.75$19.9M
KROS
Keros Therapeutics, Inc.
Oct 15, 2025
Sale(S)
Indirect
1.2M shares at avg. $17.75$21.8M
KROS
Keros Therapeutics, Inc.
Oct 15, 2025
Sale(S)
Indirect
155.3K shares at avg. $17.75$2.8M
LBRX
LB PHARMACEUTICALS INC
Sep 12, 2025
Conversion(C)
Indirect
411.7K shares-
LBRX
LB PHARMACEUTICALS INC
Sep 12, 2025
Purchase(P)
Indirect
1M shares at avg. $15.00$15.0M

		Type	Shares	Price		Ownership
Oct 15, 2025	KROS Keros Therapeutics, Inc.	Sale(S)	2,284,612	$17.75	$40,551,863	Indirect
Oct 15, 2025	KROS Keros Therapeutics, Inc.	Sale(S)	1,121,045	$17.75	$19,898,549	Indirect
Oct 15, 2025	KROS Keros Therapeutics, Inc.	Sale(S)	1,226,412	$17.75	$21,768,813	Indirect
Oct 15, 2025	KROS Keros Therapeutics, Inc.	Sale(S)	155,262	$17.75	$2,755,901	Indirect
Sep 12, 2025	LBRX LB PHARMACEUTICALS INC	Conversion(C)	411,681	-	-	Indirect
Sep 12, 2025	LBRX LB PHARMACEUTICALS INC	Purchase(P)	1,000,000	$15.00	$15,000,000	Indirect

1-6 of 6 transactions

About Pontifax Management 4 G.P. (2015) Ltd.

Pontifax Management 4 G.P. (2015) Ltd. (SEC CIK 0001726334) files insider reports with the SEC as 10% Owner of Keros Therapeutics, Inc. (KROS) and 10% Owner of LB PHARMACEUTICALS INC (LBRX).

Signal8 holds 3 ownership filings by Pontifax Management 4 G.P. (2015) Ltd. (1 Form 3, 2 Form 4), filed between Sep 11, 2025 and Oct 17, 2025. Those filings report 6 transactions, from Sep 12, 2025 to Oct 15, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on Pontifax Management 4 G.P. (2015) Ltd.'s filings is in NEW YORK, NY.

Recent filings by Pontifax Management 4 G.P. (2015) Ltd.

Oct 15, 2025: Open-market sales of KROS shares (4 lines, Form 4, code S).
Sep 12, 2025: Conversion of LBRX shares (Form 4, code C).
Sep 12, 2025: Open-market purchase of LBRX shares (Form 4, code P).

Other insiders filing for Keros Therapeutics, Inc. (KROS)

Tanini Annita, Corp. Controller & VP, Finance
Lerner Lorena Raquel, Chief Scientific Officer
Cho Esther, Chief Legal Officer
Newton Charles W., Director
BIENAIME JEAN JACQUES, Director
Prener Anne, Director

How to read Form 4 transaction codes